Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report

Ovarian clear cell carcinoma (OCCC) is a highly aggressive malignancy with a poor prognosis, and most patients experience recurrence after primary treatment. Currently, there is no standard treatment option for recurrent OCCC. Herein, we report the case of a 32-year-old female patient with OCCC. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yingchao, Jiang, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985820/
https://www.ncbi.nlm.nih.gov/pubmed/35401005
http://dx.doi.org/10.2147/OTT.S362267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985820/
https://www.ncbi.nlm.nih.gov/pubmed/35401005
http://dx.doi.org/10.2147/OTT.S362267

Ejemplares similares